COG1410 improves cognitive performance and reduces cortical neuronal loss in the traumatically injured brain

Michael R. Hoane, Nicholas Kaufman, Michael P. Vitek, Suzanne E. McKenna

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

We have previously shown that a single dose of COG1410, a small molecule ApoE-mimetic peptide derived from the apolipoprotein E (ApoE) receptor binding region, improves sensorimotor and motor outcome following cortical contusion injury (CCI). The present study evaluated a regimen of COG1410 following frontal CCI in order to examine its preclinical efficacy on cognitive recovery. Animals were prepared with a bilateral CCI of the frontal cortex. A regimen of COG1410 (0.8 mg/kg intravenously [IV]) was administered twice, at 30 min and again at 24 h post-CCI. Starting on day 11, the animals were tested for their acquisition of a reference memory task in the Morris water maze (MWM), followed by a working memory task in the MWM on day 15. Following CCI, the animals were also tested on the bilateral tactile adhesive removal test to measure sensorimotor dysfunction. On all of the behavioral tests the COG1410 group was no different from the uninjured sham group. Administration of the regimen of COG1410 significantly improved recovery on the reference and working memory tests, as well as on the sensorimotor test. Lesion analysis revealed that COG1410 significantly reduced the size of the injury cavity. Administration of COG1410 also reduced the number of degenerating neurons, as measured by Fluoro-Jade C staining, in the frontal cortex at 48 h post-CCI. These results suggest that a regimen of COG1410 appeared to block the development of significant behavioral deficits and reduced tissue loss. These combined findings suggest that COG1410 appears to have strong preclinical efficacy when administered following traumatic brain injury (TBI).

Original languageEnglish (US)
Pages (from-to)121-129
Number of pages9
JournalJournal of Neurotrauma
Volume26
Issue number1
DOIs
StatePublished - Jan 1 2009

Fingerprint

Brain
Wounds and Injuries
Frontal Lobe
Short-Term Memory
Low Density Lipoprotein Receptor-Related Protein-1
COG1410
Water
Touch
Apolipoproteins E
Adhesives
Brain Contusion
Staining and Labeling
Neurons
Peptides

Keywords

  • Behavioral recovery
  • Neuronal degeneration
  • Neuroprotection
  • Recovery of function
  • TBI
  • Trauma
  • apoE

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

COG1410 improves cognitive performance and reduces cortical neuronal loss in the traumatically injured brain. / Hoane, Michael R.; Kaufman, Nicholas; Vitek, Michael P.; McKenna, Suzanne E.

In: Journal of Neurotrauma, Vol. 26, No. 1, 01.01.2009, p. 121-129.

Research output: Contribution to journalArticle

Hoane, Michael R. ; Kaufman, Nicholas ; Vitek, Michael P. ; McKenna, Suzanne E. / COG1410 improves cognitive performance and reduces cortical neuronal loss in the traumatically injured brain. In: Journal of Neurotrauma. 2009 ; Vol. 26, No. 1. pp. 121-129.
@article{5b079b5b35464b8db09e211b9de48dba,
title = "COG1410 improves cognitive performance and reduces cortical neuronal loss in the traumatically injured brain",
abstract = "We have previously shown that a single dose of COG1410, a small molecule ApoE-mimetic peptide derived from the apolipoprotein E (ApoE) receptor binding region, improves sensorimotor and motor outcome following cortical contusion injury (CCI). The present study evaluated a regimen of COG1410 following frontal CCI in order to examine its preclinical efficacy on cognitive recovery. Animals were prepared with a bilateral CCI of the frontal cortex. A regimen of COG1410 (0.8 mg/kg intravenously [IV]) was administered twice, at 30 min and again at 24 h post-CCI. Starting on day 11, the animals were tested for their acquisition of a reference memory task in the Morris water maze (MWM), followed by a working memory task in the MWM on day 15. Following CCI, the animals were also tested on the bilateral tactile adhesive removal test to measure sensorimotor dysfunction. On all of the behavioral tests the COG1410 group was no different from the uninjured sham group. Administration of the regimen of COG1410 significantly improved recovery on the reference and working memory tests, as well as on the sensorimotor test. Lesion analysis revealed that COG1410 significantly reduced the size of the injury cavity. Administration of COG1410 also reduced the number of degenerating neurons, as measured by Fluoro-Jade C staining, in the frontal cortex at 48 h post-CCI. These results suggest that a regimen of COG1410 appeared to block the development of significant behavioral deficits and reduced tissue loss. These combined findings suggest that COG1410 appears to have strong preclinical efficacy when administered following traumatic brain injury (TBI).",
keywords = "Behavioral recovery, Neuronal degeneration, Neuroprotection, Recovery of function, TBI, Trauma, apoE",
author = "Hoane, {Michael R.} and Nicholas Kaufman and Vitek, {Michael P.} and McKenna, {Suzanne E.}",
year = "2009",
month = "1",
day = "1",
doi = "10.1089/neu.2008.0565",
language = "English (US)",
volume = "26",
pages = "121--129",
journal = "Journal of Neurotrauma",
issn = "0897-7151",
publisher = "Mary Ann Liebert Inc.",
number = "1",

}

TY - JOUR

T1 - COG1410 improves cognitive performance and reduces cortical neuronal loss in the traumatically injured brain

AU - Hoane, Michael R.

AU - Kaufman, Nicholas

AU - Vitek, Michael P.

AU - McKenna, Suzanne E.

PY - 2009/1/1

Y1 - 2009/1/1

N2 - We have previously shown that a single dose of COG1410, a small molecule ApoE-mimetic peptide derived from the apolipoprotein E (ApoE) receptor binding region, improves sensorimotor and motor outcome following cortical contusion injury (CCI). The present study evaluated a regimen of COG1410 following frontal CCI in order to examine its preclinical efficacy on cognitive recovery. Animals were prepared with a bilateral CCI of the frontal cortex. A regimen of COG1410 (0.8 mg/kg intravenously [IV]) was administered twice, at 30 min and again at 24 h post-CCI. Starting on day 11, the animals were tested for their acquisition of a reference memory task in the Morris water maze (MWM), followed by a working memory task in the MWM on day 15. Following CCI, the animals were also tested on the bilateral tactile adhesive removal test to measure sensorimotor dysfunction. On all of the behavioral tests the COG1410 group was no different from the uninjured sham group. Administration of the regimen of COG1410 significantly improved recovery on the reference and working memory tests, as well as on the sensorimotor test. Lesion analysis revealed that COG1410 significantly reduced the size of the injury cavity. Administration of COG1410 also reduced the number of degenerating neurons, as measured by Fluoro-Jade C staining, in the frontal cortex at 48 h post-CCI. These results suggest that a regimen of COG1410 appeared to block the development of significant behavioral deficits and reduced tissue loss. These combined findings suggest that COG1410 appears to have strong preclinical efficacy when administered following traumatic brain injury (TBI).

AB - We have previously shown that a single dose of COG1410, a small molecule ApoE-mimetic peptide derived from the apolipoprotein E (ApoE) receptor binding region, improves sensorimotor and motor outcome following cortical contusion injury (CCI). The present study evaluated a regimen of COG1410 following frontal CCI in order to examine its preclinical efficacy on cognitive recovery. Animals were prepared with a bilateral CCI of the frontal cortex. A regimen of COG1410 (0.8 mg/kg intravenously [IV]) was administered twice, at 30 min and again at 24 h post-CCI. Starting on day 11, the animals were tested for their acquisition of a reference memory task in the Morris water maze (MWM), followed by a working memory task in the MWM on day 15. Following CCI, the animals were also tested on the bilateral tactile adhesive removal test to measure sensorimotor dysfunction. On all of the behavioral tests the COG1410 group was no different from the uninjured sham group. Administration of the regimen of COG1410 significantly improved recovery on the reference and working memory tests, as well as on the sensorimotor test. Lesion analysis revealed that COG1410 significantly reduced the size of the injury cavity. Administration of COG1410 also reduced the number of degenerating neurons, as measured by Fluoro-Jade C staining, in the frontal cortex at 48 h post-CCI. These results suggest that a regimen of COG1410 appeared to block the development of significant behavioral deficits and reduced tissue loss. These combined findings suggest that COG1410 appears to have strong preclinical efficacy when administered following traumatic brain injury (TBI).

KW - Behavioral recovery

KW - Neuronal degeneration

KW - Neuroprotection

KW - Recovery of function

KW - TBI

KW - Trauma

KW - apoE

UR - http://www.scopus.com/inward/record.url?scp=59849124156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59849124156&partnerID=8YFLogxK

U2 - 10.1089/neu.2008.0565

DO - 10.1089/neu.2008.0565

M3 - Article

C2 - 19119914

AN - SCOPUS:59849124156

VL - 26

SP - 121

EP - 129

JO - Journal of Neurotrauma

JF - Journal of Neurotrauma

SN - 0897-7151

IS - 1

ER -